Cargando…
A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo
Abrin, a type-II ribosome inactivating protein from the seed of Abrus precatorius, is classified as a Category B bioterrorism warfare agent. Due to its high toxicity, ingestion by animals or humans will lead to death from multiple organ failure. Currently, no effective agents have been reported to t...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855095/ https://www.ncbi.nlm.nih.gov/pubmed/35185923 http://dx.doi.org/10.3389/fimmu.2022.831536 |
_version_ | 1784653578824056832 |
---|---|
author | Peng, Jingyi Wu, Jiaguo Shi, Ning Xu, Hua Luo, Longlong Wang, Jing Li, Xinying Xiao, He Feng, Jiannan Li, Xia Chai, Lihui Qiao, Chunxia |
author_facet | Peng, Jingyi Wu, Jiaguo Shi, Ning Xu, Hua Luo, Longlong Wang, Jing Li, Xinying Xiao, He Feng, Jiannan Li, Xia Chai, Lihui Qiao, Chunxia |
author_sort | Peng, Jingyi |
collection | PubMed |
description | Abrin, a type-II ribosome inactivating protein from the seed of Abrus precatorius, is classified as a Category B bioterrorism warfare agent. Due to its high toxicity, ingestion by animals or humans will lead to death from multiple organ failure. Currently, no effective agents have been reported to treat abrin poisoning. In this study, a novel anti-abrin neutralizing antibody (S008) was humanized using computer-aided design, which possessed lower immunogenicity. Similar to the parent antibody, a mouse anti-abrin monoclonal antibody, S008 possessed high affinity and showed a protective effect against abrin both in vitro and in vivo, and protected mice that S008 was administered 6 hours after abrin. S008 was found that it did not inhibit entry of abrin into cells, suggesting an intracellular blockade capacity against the toxin. In conclusion, this work demonstrates that S008 is a high affinity anti-abrin antibody with both a neutralizing and protective effect and may be an excellent candidate for clinical treatment of abrin poisoning. |
format | Online Article Text |
id | pubmed-8855095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88550952022-02-19 A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo Peng, Jingyi Wu, Jiaguo Shi, Ning Xu, Hua Luo, Longlong Wang, Jing Li, Xinying Xiao, He Feng, Jiannan Li, Xia Chai, Lihui Qiao, Chunxia Front Immunol Immunology Abrin, a type-II ribosome inactivating protein from the seed of Abrus precatorius, is classified as a Category B bioterrorism warfare agent. Due to its high toxicity, ingestion by animals or humans will lead to death from multiple organ failure. Currently, no effective agents have been reported to treat abrin poisoning. In this study, a novel anti-abrin neutralizing antibody (S008) was humanized using computer-aided design, which possessed lower immunogenicity. Similar to the parent antibody, a mouse anti-abrin monoclonal antibody, S008 possessed high affinity and showed a protective effect against abrin both in vitro and in vivo, and protected mice that S008 was administered 6 hours after abrin. S008 was found that it did not inhibit entry of abrin into cells, suggesting an intracellular blockade capacity against the toxin. In conclusion, this work demonstrates that S008 is a high affinity anti-abrin antibody with both a neutralizing and protective effect and may be an excellent candidate for clinical treatment of abrin poisoning. Frontiers Media S.A. 2022-02-04 /pmc/articles/PMC8855095/ /pubmed/35185923 http://dx.doi.org/10.3389/fimmu.2022.831536 Text en Copyright © 2022 Peng, Wu, Shi, Xu, Luo, Wang, Li, Xiao, Feng, Li, Chai and Qiao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Peng, Jingyi Wu, Jiaguo Shi, Ning Xu, Hua Luo, Longlong Wang, Jing Li, Xinying Xiao, He Feng, Jiannan Li, Xia Chai, Lihui Qiao, Chunxia A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo |
title | A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo |
title_full | A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo |
title_fullStr | A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo |
title_full_unstemmed | A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo |
title_short | A Novel Humanized Anti-Abrin A Chain Antibody Inhibits Abrin Toxicity In Vitro and In Vivo |
title_sort | novel humanized anti-abrin a chain antibody inhibits abrin toxicity in vitro and in vivo |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855095/ https://www.ncbi.nlm.nih.gov/pubmed/35185923 http://dx.doi.org/10.3389/fimmu.2022.831536 |
work_keys_str_mv | AT pengjingyi anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT wujiaguo anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT shining anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT xuhua anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT luolonglong anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT wangjing anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT lixinying anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT xiaohe anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT fengjiannan anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT lixia anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT chailihui anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT qiaochunxia anovelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT pengjingyi novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT wujiaguo novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT shining novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT xuhua novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT luolonglong novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT wangjing novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT lixinying novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT xiaohe novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT fengjiannan novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT lixia novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT chailihui novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo AT qiaochunxia novelhumanizedantiabrinachainantibodyinhibitsabrintoxicityinvitroandinvivo |